Compare
enGene Therapeutics Inc. vs Compass Therapeutics, Inc. vs Agenus Inc vs TScan Therapeutics, Inc.
| Latest fiscal year | enGene Therapeutics Inc. ENGN | Compass Therapeutics, Inc. CMPX | Agenus Inc AGEN | TScan Therapeutics, Inc. TCRX |
|---|---|---|---|---|
| Year ended | 2025-10-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | $114.20M | $10.32M |
| Revenue growth (YoY) | n/a | -100.0% | +10.4% | +266.7% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | -17.7% | n/m |
| Net margin | n/a | n/a | -2.7% | n/m |
| Net income | -$117.30M | -$66.49M | -$3.08M | -$129.77M |
| EPS (Diluted) | $2.29 | n/a | $0.00 | -$1.00 |
| Operating cash flow | -$99.24M | -$49.14M | -$77.19M | -$135.32M |
| Free cash flow | -$100.72M | -$49.17M | -$77.20M | -$139.73M |
| Cash & equivalents | $50.15M | $30.64M | $3.00M | $152.41M |
| Total assets | $221.47M | $219.59M | $226.80M | $228.79M |
| Total liabilities | $53.76M | $22.80M | n/a | $105.67M |
| Shareholders' equity | $167.71M | $196.79M | -$271.11M | $123.12M |
| Return on year-end equity | -69.9% | -33.8% | n/a | -105.4% |
| Shares outstanding | 52.02M | 178.32M | 35.32M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | enGene Therapeutics Inc. | Compass Therapeutics, Inc. | Agenus Inc | TScan Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2025-12-31 | $114.20M Ended 2025-12-31 | $10.32M Ended 2025-12-31 |
| 1 year earlier | n/a | $850.0K Ended 2024-12-31 | $103.46M Ended 2024-12-31 | $2.82M Ended 2024-12-31 |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | $156.31M Ended 2023-12-31 | $21.05M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $98.02M Ended 2022-12-31 | $13.54M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $295.67M Ended 2021-12-31 | $10.14M Ended 2021-12-31 |